Prosecution Insights
Last updated: April 19, 2026
Application No. 19/258,712

BUPROPION AS A MODULATOR OF DRUG ACTIVITY

Non-Final OA §101§DP
Filed
Jul 02, 2025
Examiner
WEDDINGTON, KEVIN E
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Antecip Bioventures II LLC
OA Round
2 (Non-Final)
75%
Grant Probability
Favorable
2-3
OA Rounds
2y 7m
To Grant
85%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
1086 granted / 1442 resolved
+15.3% vs TC avg
Moderate +10% lift
Without
With
+9.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
33 currently pending
Career history
1475
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
25.4%
-14.6% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1442 resolved cases

Office Action

§101 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are presented for examination. Applicant’s information disclosure statement and response filed February 23, 2026 have been received and entered. Accordingly, the rejections made under non-statutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 10,780,064 B2 and claims 1-20 of U.S. Patent No. 10,925,842 B2 in view of Luria, "The Validity and Reliability of the Visual Analogue Mood Scale, Journal of Psychiatric Research, Vol. 12, No. 1, pages 51-57 (1975) as set forth in the previous Office action dated December 29, 2025 at pages 2-5 as applied to claims 1-20 are hereby WITHDRAWN due to applicant’s remarks. Accordingly, the rejections made under non-statutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,191,739 B2 as set forth in the previous Office action dated December 29, 2025 at pages 5-7 as applied to claim 1 is hereby WITHDRAWN due to applicant’s remarks. Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 1-20 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-20 of copending Application No. 18/967,488 (reference application). Claims 1-20 are not allowed. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN E WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached M-F 1:30-10:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeff Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. KEVIN E. WEDDINGTON Primary Examiner Art Unit 1629 /KEVIN E WEDDINGTON/ Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Jul 02, 2025
Application Filed
Dec 13, 2025
Non-Final Rejection — §101, §DP
Feb 23, 2026
Response Filed
Mar 14, 2026
Non-Final Rejection — §101, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600696
NOVEL AROMATIC COMPOUNDS
2y 5m to grant Granted Apr 14, 2026
Patent 12599587
CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12594284
COMBINATION OF MICRONUTRIENTS TO STIMULATE THE ENDOGENOUS PRODUCTION OF HYDROGEN SULFIDE (H2S)
2y 5m to grant Granted Apr 07, 2026
Patent 12589085
USE OF DIAMINOGUANIDINE DERIVATIVE AND FEED COMPOSITION THEREOF IN PREPARATION OF VETERINARY DRUG
2y 5m to grant Granted Mar 31, 2026
Patent 12589086
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
75%
Grant Probability
85%
With Interview (+9.7%)
2y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 1442 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month